How Is NASA HRP Research Shaping Human Spaceflight Plans in 2026?

Key Takeaways

• Artemis II turned NASA HRP research into a deep-space test case for crew health.
• NASA’s 2026 planning links astronaut health science to Moon and Mars mission design.
• Commercial astronaut data is becoming part of the wider human spaceflight evidence base.

NASA HRP Research Has Shifted From Space Station Evidence to Deep-Space Decisions

April 1, 2026, gave NASA’s human research community something it had lacked since Apollo: a crewed lunar flight environment for direct measurement beyond low Earth orbit. The Artemis II mission launched four astronauts around the Moon, returned them safely on April 10, and created a data set that now sits between space station research and the planning needs of later lunar and Mars missions. NASA HRP research no longer has to rely only on International Space Station evidence, Earth analogs, and modeling when it asks how astronauts respond outside Earth’s protective neighborhood.

The Human Research Program is NASA’s main research structure for understanding astronaut health and performance risks. It uses ground laboratories, analog habitats, space station investigations, data archives, and mission-specific studies to help NASA decide how crews should train, work, eat, sleep, exercise, monitor health, and receive medical support. That work matters for Artemis because lunar missions expose crews to conditions that differ from the International Space Station: deeper space radiation, greater distance from Earth, shorter rescue options, altered communications, and tighter operational margins.

The shift in 2026 is not just scientific. It is programmatic. NASA’s Human Research Roadmap describes the Integrated Research Plan as the way HRP communicates risks, gaps, tasks, evidence reports, and research content. In practice, that means HRP is a bridge between biomedical science and engineering requirements. Research on bone loss, visual changes, immune response, radiation dose, crew coordination, and medical autonomy can influence how spacecraft, habitats, mission rules, food systems, exercise devices, and crew medical kits are designed.

For the space economy, the value of HRP research sits in the link between human performance and operational reliability. A commercial lunar delivery market, a commercial low Earth orbit station market, or a future private astronaut market cannot grow very far if crew health remains an uncertain add-on. New Space Economy has already examined how space station research contributes to Artemis II and how the International Space Station has served as a laboratory for human adaptation. NASA HRP research turns that laboratory record into standards, procedures, and risk controls that can be reused by agency missions and commercial partners.

Artemis II sharpened that need. NASA reports that the mission lasted 9 days, 1 hour, and 32 minutes, with launch on April 1 and splashdown on April 10, 2026. The crew flew beyond the distance reached by Apollo 13, according to NASA’s mission release, and conducted system checks, lunar observations, and health-related investigations during the flight. The mission did not answer every health question. Its crew size was small, the duration was short compared with Mars, and the flight profile was unique. Yet its value comes from precisely that uniqueness: it moved HRP from asking how crews live in orbit to asking how a real crew performs during a deep-space mission architecture.

The 2026 Planning Stack Connects HRP, Artemis, and Commercial Spaceflight

NASA’s 2026 planning stack for human research can be read through five layers: the Human Research Roadmap, the ongoing HRP investigations list, the 2026 Human Research Program Investigators’ Workshop, Artemis II mission research, and new solicitations tied to commercial astronaut health data. Those layers do not duplicate one another. They form a planning loop, with evidence feeding research priorities, research priorities feeding funded investigations, mission opportunities feeding new data, and new data feeding future requirements.

The HERO structure, short for Human Exploration Research Opportunities, remains the funding gateway for many HRP-supported studies. NASA’s HERO page says HRP periodically funds work that addresses risks and knowledge gaps linked to human spaceflight, and it directs researchers toward the Human Research Roadmap, NASA grant guidance, HRP grant guides, and NASA’s proposal system. For universities, companies, and medical researchers, this matters because HRP is not only an internal NASA science office. It is also a signal to the research market about which problems NASA needs solved before crews can stay longer on the Moon or travel toward Mars.

The 2026 NASA HRP Investigators’ Workshop ran virtually from April 7 to April 9, 2026. The registration site described it as HRP’s main venue for reporting progress and results from HRP-funded research and technology tasks to program management. Its session areas included Biological and Physical Sciences, Human Factors and Behavioral Performance, Human Health Countermeasures, Research Operations and Integration, the Science Integration Office, Space Radiation, the Translational Research Institute for Space Health, and other related work. That discipline list shows how broad NASA’s astronaut health problem has become. It reaches from cells and tissues to crew teams, operational procedures, radiation modeling, and medical data systems.

NASA also updated its ongoing HRP research page in January 2026. The listed work includes Artemis II investigations such as ARCHeR, Immune Biomarkers, and Artemis II Standard Measures, as well as low Earth orbit studies such as B-Complex, Brain Fluid Pressure, CIPHER, simulated manual piloting for Moon landings, Spacecraft Occupant Protection, Tempus Pro, Thigh Cuff, and Zero T2. The pattern is telling. HRP is not chasing a single cure for “spaceflight effects.” It is building an evidence base across linked systems: eyes, brain, immune function, cardiovascular function, sensorimotor function, movement, workload, sleep, stress, and operational capability.

The 2026 budget record adds another layer of tension. NASA’s FY 2026 Budget Request package included a budget summary briefing that listed $40 million for the Human Research Program to support research activities essential for Moon and Mars exploration. Budget proposals do not by themselves set final research output, but the figure shows how human research competes inside a much larger agency portfolio of launch, operations, communications, exploration systems, science missions, technology, and infrastructure. The HRP budget line is small compared with flight hardware, yet the research it supports can shape high-cost design choices for crewed missions.

The planning stack also reaches into commercial spaceflight. NASA announced a 2026 opportunity for researchers to analyze commercial astronaut health and performance data through the Translational Research Institute for Space Health’s EXPAND work. The TRISH model gives NASA a way to learn from private astronaut missions, commercial providers, and broader biomedical research communities. That structure supports a larger shift in the space economy: civilian and commercial astronaut health data can inform exploration medicine, rather than staying outside NASA’s official risk picture.

The table below summarizes the main 2026 planning items shaping NASA HRP research.

Artemis II Turned Crew Health Into Mission Data

Artemis II created a rare human research environment: a short deep-space mission with a trained crew, a new spacecraft, a lunar flyby, active physiological monitoring, and mission timelines that differed sharply from ordinary station operations. The Canadian Space Agency’s Artemis II science page describes five studies involving astronaut health, behavior, immune function, standard measures, and radiation monitoring. Those investigations are small in subject count, yet rich in context because the crew experienced a real lunar mission rather than a laboratory simulation.

ARCHeR, short for Artemis Research for Crew Health and Readiness, used wearable devices to monitor activity, sleep, stress-related measures, cognitive performance, and teamwork dynamics. That kind of study matters because crew performance problems rarely come from one cause. Sleep disruption, stress, workload, lighting, mission timing, isolation, and communication delays can interact. HRP’s Human Factors and Behavioral Performance work studies those interactions so mission planners can design schedules, crew interfaces, procedures, and support systems that reduce avoidable strain.

Immune Biomarkers examined blood and saliva samples from Artemis II crew members. Spaceflight can affect immune function, and earlier station work has shown that stressors may influence latent virus reactivation, inflammation, and infection risk. For a Mars mission, medical support cannot assume quick evacuation or rapid shipment of supplies. Better biomarker evidence can help NASA decide what to monitor, which countermeasures deserve space and mass, and how much crew medical autonomy is required.

AVATAR, short for A Virtual Astronaut Tissue Analog Response, used organ-on-a-chip devices to study how human tissue models respond to mission conditions. NASA’s Artemis II page describes the investigation as using organ chips to examine effects linked to radiation and microgravity. The research points toward a more personalized model of space medicine. A crew member’s cells can help researchers study tissue response without requiring invasive procedures during flight. That does not mean astronauts will soon receive tailor-made medical systems for every mission. It does mean HRP is moving toward predictive health models rather than relying only on population-level averages.

Standard Measures gave Artemis II another layer of value. Since 2018, Standard Measures has collected a consistent set of physiological and psychological data from participating astronauts. Extending that framework beyond low Earth orbit helps researchers compare station data with deep-space data. Consistency matters because astronaut samples are small. Every mission that collects compatible measures can strengthen the statistical value of earlier data.

Radiation monitoring addressed a defining Artemis risk. Six active sensors inside Orion and crew-worn dosimeters helped track exposure during the mission. Space radiation is not a simple “more or less” problem. Dose rate, particle type, shielding, solar activity, mission duration, and crew location inside the vehicle all matter. New Space Economy’s article on space radiation and astronaut health connects that risk to longer Artemis and Mars missions, where exposure standards, shielding design, operational shelters, and warning systems can influence mission architecture.

Artemis II did not replace the International Space Station as a human research platform. Its value lies in complementing station results. The station offers long-duration exposure to microgravity inside low Earth orbit. Artemis II offered short-duration exposure outside that region. Together, those environments help NASA compare which risks scale mainly with time, which shift with location, and which depend on mission design.

The Five Human Spaceflight Hazards Still Organize NASA’s Risk Model

NASA organizes astronaut health risk around five hazards: space radiation, isolation and confinement, distance from Earth, altered gravity, and hostile or closed environments. That structure is simple enough for public communication, but HRP translates it into specific research risks and tasks. The five hazards framework remains important because it keeps the research program tied to mission design. Every countermeasure must eventually answer an operational question: what does NASA change in the vehicle, habitat, schedule, training plan, medical plan, crew selection process, or mission rulebook?

Space radiation is the most visibly different hazard for lunar and Mars missions. The International Space Station travels within partial protection from Earth’s magnetic environment. Lunar missions travel outside that shelter. Mars missions would add longer exposure and more limited medical support. NASA’s Space Radiation Element works on radiation health outcomes, models, tissue samples, reference information, and countermeasure strategies. The problem is not only long-term cancer risk. Radiation also matters for acute mission safety, electronics, tissue effects, and how radiation combines with other stressors.

Isolation and confinement are less dramatic but operationally powerful. HRP’s Human Factors and Behavioral Performance element studies behavioral health, team structure, task performance, and life in remote conditions. Long missions can compress personal space, social options, privacy, lighting cycles, workload, and psychological recovery time. Artemis missions are shorter than Mars missions, but they provide a staged path toward understanding how crews perform when the stakes rise and Earth support becomes less immediate.

Distance from Earth changes medicine. On the International Space Station, crews can consult ground teams in near real time, receive regular cargo, and return to Earth within a shorter planning window than any Mars crew could expect. On a Mars mission, communication delays and limited resupply push the crew toward medical autonomy. That means diagnostic devices, decision-support software, training, and onboard supplies must carry more burden. Devices such as Tempus Pro, listed among ongoing HRP studies, show how remote health-data integration fits that future.

Altered gravity links Moon, Mars, and station research. Microgravity affects muscles, bones, fluids, balance, cardiovascular function, and the vestibular system, which helps people orient themselves. Lunar gravity is about one-sixth of Earth gravity, and Martian gravity is about three-eighths. HRP cannot assume that countermeasures developed for microgravity will transfer cleanly to partial gravity. Research on exercise, manual piloting after gravity transitions, balance, and reentry discomfort becomes mission design evidence.

Closed environments add biological and engineering complexity. A spacecraft is a sealed habitat with controlled atmosphere, recycled water, stored food, microbial communities, noise, vibration, lighting, limited hygiene options, and shared surfaces. HRP’s Human Health Countermeasures work touches many of those issues through nutrition, microbiome studies, immune research, bone and muscle research, and medical standards. New Space Economy’s coverage of NASA’s Human Health and Performance Directorate gives wider context on how health evidence connects to operational safety.

The table below maps the hazard structure to research and planning decisions.

Low Earth Orbit Remains the Main Human Research Workbench

The International Space Station remains NASA’s richest crewed microgravity research platform, even after Artemis II added a deep-space data point. HRP’s 2026 ongoing research list shows why. Studies such as CIPHER, B-Complex, Brain Fluid Pressure, Thigh Cuff, Standard Measures, and Zero T2 depend on repeated observations, longer mission exposure, crew participation, and access to station facilities. A lunar flyby can produce valuable measurements, but the station still provides time, repeatability, and access.

CIPHER is a good example of system-level research. The study examines how the human body changes in orbit through multiple connected studies across body systems. The logic matches the real spaceflight problem. Bone, muscle, brain, vision, immune function, cardiovascular adaptation, sleep, and workload do not change in isolation. A countermeasure that helps one system can affect another. NASA HRP research has to understand combined effects because missions carry limited mass, volume, crew time, and medical options.

Research on brain and eye changes also remains central. Some astronauts experience vision-related changes associated with spaceflight, and scientists have investigated links among fluid shifts, pressure, anatomy, genetics, nutrition, and mission duration. B-Complex examines whether daily B vitamin supplementation can prevent or reduce brain and eye changes that affect some space travelers. Brain Fluid Pressure and Spinal Fluid Biomarkers pursue related questions from different angles. These studies matter because a Mars crew cannot treat vision loss as an inconvenience. Reading displays, navigating procedures, repairing systems, piloting vehicles, and performing science tasks all require reliable human performance.

Manual piloting studies connect physiology to mission operations. NASA’s ongoing HRP list includes research on how gravity transitions may affect astronaut piloting for future Moon landings. That connects directly to Artemis operations. A crew may move from Earth gravity to launch acceleration, microgravity, lunar orbit, partial gravity, and reentry. Even short-term disorientation can matter during landing, docking, suit operations, rover driving, or surface emergency response.

Spacecraft Occupant Protection looks at reentry discomfort and sensor data. This may sound narrow, but it points to a larger design issue. Human-rated vehicles are built around survival, but future mission planners also need to know how crews function immediately after landing. If astronauts land on the Moon or Mars after extended exposure to altered gravity, their ability to egress, walk, operate vehicles, or respond to a problem becomes an operational measure, not a medical afterthought.

New Space Economy’s article on International Space Station experiments describes the station as a research setting where microgravity changes behavior in flames, fluids, cells, plants, materials, and human physiology. For HRP, the human element remains the station’s highest-value exploration contribution. It is where researchers can collect repeated crew data and test countermeasures before risking them on missions where rescue options narrow.

The challenge is continuity. NASA plans to retire the International Space Station after a transition period to commercial low Earth orbit destinations. New Space Economy’s article on whether NASA can avoid a low Earth orbit gap notes that commercial stations may initially offer less total research capability than the station. HRP research will need enough crew time, laboratory capacity, upmass, downmass, data flow, privacy protections, and operational stability to keep long-running studies alive.

Commercial Astronaut Data Is Becoming Part of the Evidence Base

Private astronaut missions have changed the human research problem. NASA once centered human spaceflight health evidence on government astronauts selected, trained, and monitored through national programs. The commercial market adds shorter missions, more diverse participant backgrounds, different training pipelines, and privately operated vehicles. That does not automatically make the data easier to use. It can make the evidence base richer if NASA, TRISH, providers, and participants can solve consent, privacy, standardization, data quality, and access issues.

NASA’s 2026 announcement inviting proposals to analyze commercial astronaut health and performance data through TRISH’s EXPAND initiative points in that direction. EXPAND collects biomedical data before, during, and after commercial spaceflight, then curates de-identified data and biological samples for selected researchers. The 2026 data-analysis opportunity offered access to data rather than a direct monetary grant, with limited technical support to help researchers understand data dictionaries and study protocols. That is a planning choice as much as a funding choice. It makes commercial astronaut data a research infrastructure asset.

Civilian data can help answer questions that government astronaut cohorts cannot answer alone. Professional astronauts are screened, trained, and medically monitored under demanding standards. Private astronauts may include older participants, people with different medical backgrounds, and people flying for shorter durations. That variation can help researchers understand which risks apply broadly and which risks depend on selection, age, prior health, mission duration, workload, or training. New Space Economy’s coverage of civilian human research fits the same theme: commercial human spaceflight needs a health research system that recognizes civilians as part of the future crew population.

This expansion raises governance questions. Health data is sensitive. Commercial astronaut data can involve consent agreements, de-identification limits, proprietary mission details, and small sample sizes that may make anonymity harder than it looks. A four-person mission, or even a larger private astronaut set, can sometimes be easier to re-identify than an ordinary medical data set. HRP and TRISH must balance research value against privacy, trust, and participant willingness.

The market link is direct. Space tourism, commercial stations, orbital research services, and future private lunar services all need credible risk management. Insurers, regulators, providers, investors, and customers will ask how well operators understand health risks. Better data does not remove risk, but it can help price risk, design training, set screening criteria, improve consent language, choose medical equipment, and build emergency protocols. A maturing commercial human spaceflight sector will need this evidence as much as it needs rockets.

Commercial low Earth orbit destinations create another connection. NASA wants future stations to support agency research, private research, manufacturing experiments, astronaut training, and commercial activity. Human research will compete for rack space, crew time, and vehicle logistics. New Space Economy has explored the commercial station business problem from the perspective of market fit. HRP adds another test: commercial stations must be good enough laboratories for exploration research, not just tourist venues or manufacturing platforms.

NASA HRP research in 2026 sits at that junction. It depends on government missions, but it increasingly reaches into commercial data flows. It supports Artemis, but it also helps shape the medical and operational norms that future private operators may adopt.

The Data Problem Is as Important as the Biology

Artemis II exposed a problem that will keep growing: small crew data sets are scientifically valuable and statistically difficult. Four astronauts can generate immense physiological, behavioral, imaging, tissue, and radiation data. Yet conventional biomedical research often depends on larger samples. NASA’s Artemis II Human Research Data Methodology Challenge addressed that difficulty directly by seeking methods to analyze complex, multi-system, time-based data from a small crew. The challenge opened March 30, 2026, offered $25,000 in total prizes, and closed June 5, 2026.

The methodological issue is not academic housekeeping. Space medicine cannot wait for thousands of deep-space astronauts to build perfect data sets. HRP has to make decisions with sparse data, historical astronaut records, space station observations, ground analogs, animal studies, cell and tissue models, radiation models, and commercial astronaut data. Those streams differ in quality and relevance. A Mars mission planner cannot treat them as interchangeable.

This is where artificial organ models, standard measures, and computational methods become planning tools. AVATAR organ-chip work can help examine tissue response. Standard Measures makes repeated astronaut observations more comparable. CIPHER collects multi-system data. Radiation sensors quantify the environment. Commercial astronaut data increases diversity. Earth analogs provide larger human cohorts under controlled isolation or mission-like stress. No single source is enough. The value comes from combining them carefully without overstating what each can prove.

NASA’s Life Sciences Data Archive and Open Science Data Repository also matter. HRP’s main page identifies NASA life sciences databases as places where human, animal, cell, and plant research data are archived. Open science is not simply a publication value. It can increase the number of researchers who test HRP assumptions, reanalyze data, and develop methods. The bottleneck becomes data quality, metadata, privacy protection, and compatibility across studies.

The space economy connection is growing. Companies building crew medical devices, wearable monitors, telemedicine systems, habitat software, human-machine interfaces, exercise equipment, and analytics platforms all need access to research priorities and standards. If HRP methods move toward continuous monitoring, personalized countermeasures, remote diagnostics, and predictive modeling, supplier markets will follow. NASA’s procurement and research signals can influence product design long before a commercial market is large enough to support those products alone.

The data problem also affects regulation. Commercial human spaceflight remains less medically standardized than government astronaut flight. As private missions increase, regulators may face pressure to define health-data norms, incident reporting expectations, informed consent standards, and emergency care requirements. HRP does not write all those rules, but its research base can inform the evidence that policymakers use.

The Space Economy Depends on Keeping Human Research Continuous

Human research continuity is a strategic asset. If the International Space Station transitions to commercial destinations with a research gap, HRP could lose repeated measurements, trained crew participation, long-duration microgravity exposure, and operational routines that took decades to build. That risk does not mean commercial stations cannot work. It does mean NASA must treat human research capability as a core service requirement, not a leftover after tourism, media, and manufacturing are priced.

Commercial stations will need to support more than a few experiments. HRP research may require crew privacy, biological sampling, cold storage, specialized hardware, downmass for samples, telemedicine testing, exercise device evaluation, compatible data standards, and careful scheduling. Some of those needs do not fit easily with high-turnover tourist operations. Others may conflict with proprietary manufacturing workflows. Station operators that can support biomedical research well may gain an advantage with NASA as an anchor customer.

New Space Economy’s analysis of whether NASA can replace the station without a LEO gap highlights that the replacement problem is not only about keeping humans in orbit. It is about preserving the functions the station performs. HRP research is one of those functions. Without it, Artemis and Mars planning would become more dependent on models and shorter mission samples.

Workforce continuity also matters. Space medicine draws from physicians, physiologists, neuroscientists, psychologists, radiation biologists, data scientists, engineers, statisticians, nutrition specialists, exercise scientists, operations planners, and flight surgeons. Funding interruptions can scatter expertise. Long-running studies can lose continuity. Methods can become harder to compare. For an agency planning Moon and Mars missions, that loss could cost more than it saves.

The private market can help, but it cannot yet replace the public research role. Commercial operators have incentives to improve passenger safety and mission reliability. They may not have incentives to fund open-ended research on low-probability, high-impact, long-term health outcomes. NASA HRP research fills that gap because exploration missions require knowledge that is too early, too specialized, or too public-good oriented for the commercial market to fund alone.

Artemis also pulls HRP toward lunar surface work. New Space Economy’s broader coverage of the Artemis program places lunar missions inside a wider exploration architecture. HRP’s contribution to that architecture includes partial-gravity adaptation, spacesuit workload, decompression sickness prevention, dust exposure, radiation monitoring, habitat medicine, nutrition, sleep, and cognitive performance during surface operations. These are not glamorous hardware items, but they can define whether crews can work safely and productively.

A deeper Mars path makes the same point stronger. New Space Economy’s Three Steps to Mars article frames Mars as a staged challenge. HRP supplies much of the human evidence needed for that staging. Without validated countermeasures, Mars mission architecture becomes an engineering plan wrapped around unproven human assumptions.

What NASA’s 2026 HRP Plans Suggest for Moon and Mars Missions

NASA’s 2026 HRP planning suggests a shift toward integrated, mission-tied human research rather than isolated biomedical studies. Artemis II supplied a real deep-space crew data point. HRP IWS 2026 gathered research progress across multiple disciplines. HERO preserved a proposal pathway for risk-driven studies. TRISH’s EXPAND work opened commercial astronaut data for analysis. The Artemis II data methodology challenge recognized that deep-space health data will be small, complex, and hard to interpret.

For Moon missions, the near-term research priorities are likely to stay practical: radiation monitoring, operational health checks, sleep and workload, crew teamwork, motion sickness, landing readiness, immune changes, spacesuit-related risks, nutrition, and recovery after flight. Surface missions will add lunar dust, partial gravity, extravehicular activity, rover operations, habitat systems, and emergency medicine. Many of these topics connect directly to mission schedules and hardware design.

For Mars, the planning burden grows. A Mars mission would require far longer duration, greater autonomy, deeper isolation, greater communication delay, and more demanding medical self-sufficiency. HRP must help answer questions that affect architecture: how much shielding is enough, what medical conditions must be treatable onboard, how much exercise hardware is required, how crews should be selected and supported, how much privacy and habitable volume are needed, and how to keep performance stable over months or years.

The most important change in 2026 is that NASA now has a fresh lunar mission data stream to place beside station evidence. Artemis II did not resolve the Mars health problem, and it did not make station research less valuable. It gave HRP a new calibration point. That calibration point can make models better, improve future study design, and guide what researchers seek from Artemis III, Artemis IV, commercial stations, analog missions, and private astronaut flights.

NASA HRP research also suggests that future exploration success will depend on the invisible infrastructure of human performance: sleep, food, medical data, radiation sensing, immune monitoring, team design, privacy, exercise, interfaces, and decision support. Rockets and landers make missions possible. Human research determines whether crews can complete the work once they get there.

Summary

NASA HRP research in 2026 is best understood as a planning system for human reliability in space. Artemis II added a deep-space crew data point, the HRP Investigators’ Workshop organized a cross-disciplinary research community, HERO continued risk-driven funding pathways, and TRISH’s EXPAND initiative widened the evidence base through commercial astronaut data. Together, these activities show NASA moving from station-centered knowledge toward a mixed model built from the International Space Station, lunar missions, commercial flights, analogs, tissue models, and data science.

The result is a more complicated but more useful research environment. Human spaceflight no longer belongs only to government astronauts on government vehicles. It now includes commercial crews, private passengers, future lunar surface teams, station operators, medical-device suppliers, insurers, and regulators. HRP remains central because it turns health uncertainty into mission design evidence.

The 2026 record also shows a constraint. HRP’s research line is small compared with launch vehicles, spacecraft, and lunar infrastructure. Yet crew health science can change the design of all of them. For Moon and Mars planning, the question is less whether NASA can fly humans farther. Artemis II showed that it can. The harder question is how NASA, commercial partners, and international agencies will keep humans healthy, capable, and medically supported as missions become longer, more remote, and more operationally demanding.

Appendix: Useful Books Available on Amazon

• Packing for Mars: The Curious Science of Life in the Void
• Fundamentals of Space Medicine
• Space Physiology and Medicine: From Evidence to Practice
• Human Spaceflight: Mission Analysis and Design
• Safe Passage: Astronaut Care for Exploration Missions
• Space Safety and Human Performance

Appendix: Top Questions Answered in This Article

What Is NASA HRP Research?

NASA HRP research is the work of NASA’s Human Research Program, which studies how spaceflight affects astronaut health and performance. It connects biomedical science, behavioral research, radiation studies, operational medicine, and data systems to mission planning for low Earth orbit, lunar missions, and future Mars missions.

Why Did Artemis II Matter for Human Research?

Artemis II mattered because it gave NASA new crew health and performance data from deep space. Earlier research relied heavily on the International Space Station, Earth analogs, and models. Artemis II added mission data from a lunar flyby, including radiation monitoring, crew health measures, and behavioral performance studies.

What Are the Five NASA Human Spaceflight Hazards?

NASA organizes human spaceflight hazards into space radiation, isolation and confinement, distance from Earth, altered gravity, and hostile or closed environments. These categories help NASA connect research questions to practical mission decisions such as shielding, medical autonomy, exercise systems, habitat design, and crew support.

What Was New in NASA HRP Planning During 2026?

Key 2026 planning activity included Artemis II human research, the 2026 HRP Investigators’ Workshop, updated ongoing HRP research listings, the Artemis II data methodology challenge, and a TRISH opportunity to analyze commercial astronaut health data. These efforts linked mission data, research funding, and commercial spaceflight evidence.

How Does HRP Use the International Space Station?

HRP uses the International Space Station as a long-duration microgravity laboratory for studying astronaut physiology, psychology, medical systems, exercise, nutrition, vision changes, immune response, and operational performance. The station remains valuable because it provides repeated observations over longer periods than short lunar missions.

Why Is Commercial Astronaut Data Useful to NASA?

Commercial astronaut data can broaden the evidence base beyond professional astronaut cohorts. Private missions may include participants with different ages, backgrounds, training histories, and mission profiles. If managed with strong consent and privacy safeguards, those data can help researchers understand risks for a wider human spaceflight population.

How Does HRP Research Affect Spacecraft and Habitat Design?

HRP research can influence shielding, exercise equipment, food systems, sleep schedules, lighting, medical kits, sensor placement, crew interfaces, habitat volume, and mission rules. The program’s value comes from turning health risks into design requirements that engineers and mission planners can use.

Why Is Radiation Such a Difficult Problem for Artemis and Mars?

Radiation risk depends on particle type, dose, shielding, solar activity, mission duration, and the crew’s location inside the vehicle or habitat. Lunar and Mars missions operate beyond much of Earth’s natural protection, so NASA needs better monitoring, shelter rules, exposure models, and countermeasures.

Could Commercial Space Stations Replace the ISS for HRP Research?

Commercial stations could support HRP research if they provide enough crew time, laboratory hardware, sample storage, privacy, data systems, and logistics. A simple human presence in orbit is not enough. NASA needs research capability that can continue long-duration studies without losing data continuity.

What Does NASA HRP Research Mean for Mars Missions?

Mars missions require medical autonomy, radiation management, long-duration crew performance, reliable exercise systems, behavioral support, and closed-habitat health controls. NASA HRP research supplies the evidence needed to design those systems before crews commit to missions where quick rescue is impossible.

Appendix: Glossary of Key Terms

NASA HRP

NASA HRP means NASA’s Human Research Program. It studies health and performance risks associated with human spaceflight and develops evidence, countermeasures, data systems, and research priorities that support missions in low Earth orbit, around the Moon, on the lunar surface, and eventually toward Mars.

Artemis II

Artemis II was NASA’s crewed lunar flyby mission launched on April 1, 2026, and recovered on April 10, 2026. It carried astronauts around the Moon aboard Orion and created a deep-space mission data set for spacecraft testing, crew performance, human research, and future Artemis planning.

Human Research Roadmap

The Human Research Roadmap is NASA’s web-based tool for communicating HRP risks, gaps, evidence reports, tasks, reviews, and Integrated Research Plan content. It helps researchers and planners understand which health and performance questions NASA is trying to resolve for future human exploration.

HERO

Human Exploration Research Opportunities, or HERO, is NASA’s funding pathway for many HRP-related studies. Through HERO solicitations, researchers can propose work that addresses astronaut health, performance, radiation, medical capability, human factors, operational integration, and other exploration-linked research needs.

TRISH

The Translational Research Institute for Space Health is a NASA-supported institute that funds and coordinates research to help protect human health during deep-space exploration. TRISH also works with commercial spaceflight providers through efforts such as EXPAND, which gathers private astronaut health and performance data.

EXPAND

EXPAND is a TRISH initiative that collects, organizes, and shares de-identified biomedical data and samples from commercial spaceflight participants. Its purpose is to help qualified researchers study how a broader human population responds to spaceflight before, during, and after missions.

ARCHeR

ARCHeR stands for Artemis Research for Crew Health and Readiness. It is an Artemis II study that used wearable devices and related measures to examine sleep, activity, stress, cognitive performance, and teamwork during a deep-space mission environment.

Standard Measures

Standard Measures is a NASA research framework that collects consistent physiological and psychological data from astronauts. It improves comparison across missions by using common measures before, during, and after flight, making small astronaut data sets more useful over time.

Space Radiation

Space radiation refers to high-energy particles found outside Earth’s protective atmosphere and magnetic environment. It can affect human tissue, spacecraft electronics, and mission operations, making radiation monitoring, shielding, exposure rules, and biological research central to lunar and Mars planning.

Commercial Low Earth Orbit Destinations

Commercial low Earth orbit destinations are privately developed space stations or habitats intended to succeed some International Space Station functions. NASA expects them to support research, crew operations, technology development, and commercial activity after the ISS transition.